Compare Rocket Lab USA Inc (RKLB) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Tempus AI — how do they compare? Rocket Lab USA Inc trades at $69.47 (market cap $43.74B), while Tempus AI trades at $70.26 (market cap $12.58B). The key difference: Rocket Lab USA Inc is far larger — about 3.5× Tempus AI's market cap, and Tempus AI is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Tempus AI for 22 Days on average.
| RKLB | TEM | |
|---|---|---|
Market Cap | $43.74B | $12.58B |
Volume | 22,892,581 | 7,444,569 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $150.23 | $99.28 |
52-Week Low | $39.48 | $41.55 |
Typical Hold Time | 29 Days | 22 Days |
Enterprise Value | $41.57B | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $71.92, down 4.18% today, with neutral technical signals and strong analyst support. The company recently secured its largest commercial Electron deal - 20 launches with Synspective - boosting its backlog past 100 missions. Despite negative profitability metrics, revenue growth continues with 2026 projections showing improvement from 2025's $602 million. The stock trades at elevated valuation multiples with P/S of 51.96 and P/B of 12.52.
RKLB presents a growth story with significant contract wins and expanding launch capacity, though profitability remains elusive. The 76% analyst buy rating and $107 consensus target suggest substantial upside potential. Key risks include intense SpaceX competition, high cash burn, and valuation concerns. Investors must weigh growth trajectory against persistent losses and competitive pressures in the evolving space industry.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
